Table 2. PCa Detection Rate in the Subjects with PI-RADS v2 Score 3 on MRI.

Study (Year)	Study Design	MRI Scanner	Subject No.	Subject No. with Score 3 (%)	Cancer Detection Rate (%)
					Overall PCa	CSC
Tan et al. (2017) [36]	Retrospective	3T	134 lesions	31 lesions (23)	19	10
Venderink et al.* (2018) [38]	Retrospective	3T	1057 male	156 male (15)	35	17
Rosenkrantz et al. (2017) [34]	Retrospective	3T	343 lesions	79 lesions (23)	28	11
Kasivisvanathan et al. (2018) [31]	Prospective	1.5 or 3T	252 male	51 male (20)	33	12
Sheridan et al. (2018) [37]	Retrospective	3T	474 lesions	111 lesions (23)	27	17
van der Leest et al. (2019) [29]	Prospective	3T	317 male	40 male (13)	35	18
Wegelin et al. (2019) [39]	Prospective	3T	665 male	64 male (10)	25	17
Westphalen et al. (2020) [35]	Retrospective	1.5 or 3T	5082 lesions	1490 lesions (29)	30	15

^*This study utilized both PI-RADS v1 and v2. CSC = clinically significant cancer, MRI = magnetic resonance imaging, PCa = prostate cancer, PI-RADS = Prostate Imaging Reporting and Data System